Saturday, July 11, 2015 11:21:37 AM
Pfizer’s Next-Generation Human Growth Hormone Takes a Step Forward
Enrollment is complete in Pfizer and Opko Health’s phase 3 study of hGH-CTP for human growth hormone deficiency.
The Motley Fool
Jul 11, 2015 at 7:56AM
Todd Campbell Fool Contributor
In a bid to protect sales for its human growth hormone drug Genotropin, Pfizer (NYSE:PFE) licensed rights to a longer-lasting human growth hormone therapy, hGH-CTP, in December. This longer-lasting drug has just completed enrollment in a key phase 3 trial that could clear the way for a potential FDA filing next year.
Reimagining care
Because human growth hormone deficiency can slow or halt the body’s ability to grow, human growth hormone is used to treat tens of thousands of children and adults who don’t adequately produce enough of the hormone naturally. Typically, patients with human growth hormone deficiency are identified by the time they are between two and three years old. However, while most people are born with human growth hormone deficiency, it can also be caused by other medical conditions or injuries.
Currently, a host of companies, including Pfizer, market therapies that are injected daily to make up for the deficiency, and often this treatment continues throughout a patient’s lifetime. Because of the daily injection schedule and the chronic nature of this condition, companies like Pfizer are working on therapies to ease patient burden.
In Pfizer’s case, hGH-CTP, which was licensed from Opko Health, could revolutionize patient treatment by reducing injections to once per week. Currently, hGH-CTP is in phase 3 trials for use in adults, and phase 2 trials for use in children.
A billion dollar market opportunity
Pfizer’s Genotropin is one of the most widely-used human growth therapies, but a host of other companies, including market-share leader Novo Nordisk, also market treatments.
Last year, Pfizer’s sales of Genotropin totaled $723 million, and in the first quarter, Genotropin revenue was $138 million. Meanwhile, over at Novo Nordisk, sales of its Norditropin totaled $973 million in 2014, and $274 million in the first quarter at current exchange rates. The ability to protect Genotropin revenue and conceivably win away share from others like Novo Nordisk suggests that Pfizer’s deal to license Opko Health’s hGH-CTP may prove to be savvy.
Pfizer paid Opko Health $295 million up front, and agreed to pay up to an additional $275 million in milestones, as well as royalties, on any eventual global sales, to get rights to hGH-CTP. Additionally, if hGH-CTP is effective in children, Pfizer will split any eventual profit from both hGH-CTP and Genotropin with Opko Health.
Looking forward
Now that enrollment in the adult study of hGH-CTP is complete, all eyes turn to 2016, when phase 3 trial results are expected to be released in the second half of the year. If those results are positive, then a regulatory filing could follow shortly thereafter.
If so, then Pfizer could be in a position to unleash its Genotropin marketing team to begin pitching hGH-CTP at some point in 2017. Granted, that timeline means that any benefit of hGH-CTP to Pfizer and Opko Health’s bottom line is still a ways off, but given that hGH-CTP could mark the biggest advance in treating human growth hormone deficiency in decades, it’s worth keeping an eye on.
Todd Campbell has no position in any stocks mentioned. Todd owns the equity research firm E.B. Capital Markets, LLC. E.B. Capital’s clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Recent OPK News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:29:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:07:44 PM
- OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 09:02:37 PM
- AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • GlobeNewswire Inc. • 03/05/2024 01:52:22 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 09:05:23 PM
- NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st • PR Newswire (US) • 02/28/2024 02:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:07:54 PM
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/16/2024 09:53:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:07:24 PM
- NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China • PR Newswire (US) • 02/05/2024 01:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 08:30:14 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:00:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:09:07 PM
- OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes • GlobeNewswire Inc. • 01/09/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 02:10:34 PM
- OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM